Pfizer Inc. (NYSE:PFE) Given Consensus Recommendation of “Hold” by Analysts

Shares of Pfizer Inc. (NYSE:PFEGet Free Report) have received a consensus rating of “Hold” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $36.93.

Several brokerages have commented on PFE. Wells Fargo & Company cut their target price on Pfizer from $39.00 to $35.00 and set an “equal weight” rating on the stock in a research note on Monday, October 16th. JPMorgan Chase & Co. lowered their target price on Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, October 16th. BMO Capital Markets decreased their price target on Pfizer from $44.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, January 31st. Finally, Jefferies Financial Group raised Pfizer from a “hold” rating to a “buy” rating and raised their price target for the company from $38.00 to $39.00 in a report on Monday, October 16th.

View Our Latest Research Report on Pfizer

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb bought 3,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were acquired at an average cost of $26.47 per share, with a total value of $79,410.00. Following the purchase, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $238,230. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently bought and sold shares of PFE. Worth Asset Management LLC acquired a new position in Pfizer during the first quarter worth about $29,000. Briaud Financial Planning Inc purchased a new position in Pfizer during the third quarter worth approximately $30,000. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new position in Pfizer during the third quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. 68.05% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.4 %

Shares of PFE stock opened at $27.67 on Tuesday. Pfizer has a 1-year low of $25.76 and a 1-year high of $44.20. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.38 and a quick ratio of 2.05. The business has a 50-day moving average of $28.16 and a 200 day moving average of $31.30. The stock has a market capitalization of $156.21 billion, a PE ratio of 76.85, a P/E/G ratio of 1.22 and a beta of 0.62.

Pfizer (NYSE:PFEGet Free Report) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.61% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the company earned $1.14 EPS. The business’s revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer will post 2.23 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 26th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, January 25th. This is a boost from Pfizer’s previous quarterly dividend of $0.41. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.07%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Pfizer Company Profile

(Get Free Report

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.